Verona Pharma (VRNA) Scheduled to Post Earnings on Monday

Verona Pharma (NASDAQ:VRNA - Get Free Report) will be announcing its earnings results before the market opens on Monday, November 4th. Analysts expect the company to announce earnings of ($0.44) per share for the quarter. Persons interested in participating in the company's earnings conference call can do so using this link.

Verona Pharma (NASDAQ:VRNA - Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.53). During the same period in the previous year, the business earned ($0.11) earnings per share. On average, analysts expect Verona Pharma to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Verona Pharma Stock Down 2.2 %

Verona Pharma stock traded down $0.75 during midday trading on Monday, hitting $33.11. 548,051 shares of the company were exchanged, compared to its average volume of 911,937. The company's fifty day moving average price is $29.96 and its 200-day moving average price is $21.54. The company has a market cap of $2.69 billion, a PE ratio of -21.99 and a beta of 0.44. The company has a debt-to-equity ratio of 0.72, a current ratio of 8.61 and a quick ratio of 8.61. Verona Pharma has a fifty-two week low of $11.39 and a fifty-two week high of $35.62.

Wall Street Analysts Forecast Growth

Several research firms recently commented on VRNA. Truist Financial boosted their price target on Verona Pharma from $38.00 to $44.00 and gave the stock a "buy" rating in a research report on Wednesday, October 9th. HC Wainwright reissued a "buy" rating and set a $36.00 price target on shares of Verona Pharma in a research report on Tuesday, October 1st. Wells Fargo & Company began coverage on Verona Pharma in a research report on Thursday, October 3rd. They issued an "overweight" rating and a $50.00 target price on the stock. Finally, Canaccord Genuity Group upped their target price on Verona Pharma from $35.00 to $37.00 and gave the company a "buy" rating in a research report on Monday, July 22nd. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Verona Pharma presently has a consensus rating of "Buy" and an average target price of $39.33.

Insider Buying and Selling at Verona Pharma

In related news, CEO David Zaccardelli sold 110,456 shares of the company's stock in a transaction that occurred on Monday, October 21st. The stock was sold at an average price of $4.38, for a total transaction of $483,797.28. Following the sale, the chief executive officer now directly owns 14,894,464 shares of the company's stock, valued at approximately $65,237,752.32. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, CFO Mark W. Hahn sold 116,696 shares of the company's stock in a transaction that occurred on Monday, October 21st. The stock was sold at an average price of $4.38, for a total transaction of $511,128.48. Following the sale, the chief financial officer now directly owns 13,973,264 shares of the company's stock, valued at approximately $61,202,896.32. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO David Zaccardelli sold 110,456 shares of the company's stock in a transaction that occurred on Monday, October 21st. The shares were sold at an average price of $4.38, for a total value of $483,797.28. Following the sale, the chief executive officer now directly owns 14,894,464 shares in the company, valued at approximately $65,237,752.32. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 868,840 shares of company stock valued at $3,805,519 in the last three months. Corporate insiders own 4.80% of the company's stock.

Verona Pharma Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.